(Press-News.org) 7 May, 2013 -- Sydney, Australia:
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.
The research involves the drug Dz13, a targeted molecular therapy, which was developed at the University of New South Wales (UNSW) and has now been found to be safe in a clinical trial of patients with the common skin cancer, basal-cell carcinoma.
"This is the first report of a drug of this type to be used in humans," says UNSW Medicine's Professor Levon Khachigian, who has been developing the DNAzyme technology for 10 years.
"It's a smart drug, which targets a bad protein that controls tumour growth and spread," says Professor Khachigian, the Director of the UNSW Centre for Vascular Research. The collaborative trial was conducted by researchers from UNSW, the University of Sydney and Royal Prince Alfred Hospital.
The findings have been published today in the prestigious journal The Lancet.
"Even though we were only testing for safety, there were unexpected positive effects," says Professor Khachigian.
"The drug knocked down levels of this bad protein and the tumours shrunk in the majority of patients."
The researchers hope subsequent trials will prove that larger doses of the drug over a longer time period will be more effective.
"Targeted molecular therapy like this might also offer novel, effective, and less invasive therapeutic options for basal-cell carcinoma," says Professor Gary Halliday, from the University of Sydney, who is one of the co-authors of the study.
If the next stages of the clinical trials in basal-cell carcinoma are successful, the researchers hope that within three years, the drug could be used as a treatment for these cancers, reducing scarring and the costs and inconvenience associated with surgery.
Basal-cell carcinoma is the most common cancer among fair-skinned people worldwide with Australia having the highest incidence.
"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in a range of diseases," says Professor Khachigian, who predicts that melanoma and eye diseases including macular degeneration and diabetic retinopathy are the likely future targets for research.
A phase one trial in skin melanoma is expected to begin in a month.
###
Media contact: Susi Hamilton, UNSW media END
New class of drug targets skin cancer
2013-05-07
ELSE PRESS RELEASES FROM THIS DATE:
New perspective needed for role of major Alzheimer's gene
2013-05-07
Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found.
People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer's disease compared with those who have other variations of the gene.
Many researchers believe that the memory loss and cognitive problems of Alzheimer's result from the buildup over many years of brain amyloid plaques. The plaques are made mostly of a sticky substance called amyloid ...
A giant leap to commercialization of polymer solar cell
2013-05-07
A polymer solar cell is a type of thin film solar cells made with polymers that produce electricity from sunlight by the photovoltaic effect. Most current commercial solar cells are made from a highly purified silicon crystal. The high cost of these silicon solar cells and their complex production process has generated interest in developing alternative photovoltaic technologies.
Compared to silicon-based devices, PSCs are lightweight (which is important for small autonomous sensors), solution processability (potentially disposable), inexpensive to fabricate (sometimes ...
New insights into Ebola infection pave the way for much-needed therapies
2013-05-07
The Ebola virus is among the deadliest viruses on the planet, killing up to 90% of those infected, and there are no approved vaccines or effective therapies. A study published by Cell Press on May 7th in the Biophysical Journal reveals how the most abundant protein making up the Ebola virus—viral protein 40 (VP40)—allows the virus to leave host cells and spread infection to other cells throughout the human body. The findings could lay the foundation for the development of new drugs and strategies for fighting Ebola infection.
"Little research is available on how the ...
Protecting the heart health of diabetic patients
2013-05-07
Diabetics have an increased risk of developing coronary artery disease and plaque build-up in their arteries, even if they receive cholesterol-lowering therapies. New research published in the May 7th issue of the Cell Press journal Cell Metabolism reveals that high blood sugar levels also boost the production of inflammatory cells, which contribute to plaque build-up in blood vessels. The researchers identify the cause of this increased production in inflammatory cells and find that blocking this new pathway could help safeguard the heart health of diabetic patients.
"We ...
Biomechanical performances of old-fashioned leather and modern football helmets
2013-05-07
Charlottesville, VA (May 7, 2013). Researchers at the Center for Injury Biomechanics at Virginia Tech in Blacksburg, Virginia compared the relative safety afforded by two 1930-vintage leather football helmets and 10 modern football helmets during impacts to players' heads. These researchers found that all 10 modern helmets provided significantly more protection than leather helmets used in the first half of the twentieth century, and demonstrated that differences also exist between modern helmets. Details on their methods and findings are found in "Biomechanical performance ...
Type 1 diabetes and heart disease linked by inflammatory protein
2013-05-07
NEW YORK, NY (May 7, 2013) — Type 1 (insulin-dependent) diabetes appears to increase the risk of heart disease, the leading cause of death among people with high blood sugar, partly by stimulating the production of calprotectin, a protein that sparks an inflammatory process that fuels the buildup of artery-clogging plaque. The findings, made in mice and confirmed with human data, suggest new therapeutic targets for reducing heart disease in people with type 1 diabetes. Led by Columbia University Medical Center (CUMC) researchers in collaboration with investigators at New ...
Study of new 'bone-head' hints at higher diversity of small dinosaurs
2013-05-07
Toronto, Canada – Scientists have named a new species of bone-headed dinosaur (pachycephalosaur) from Alberta, Canada. Acrotholus audeti (Ack-RHO-tho-LUS) was identified from both recently discovered and historically collected fossils. Approximately six feet long and weighing about 40 kgs in life, the newly identified plant-eating dinosaur represents the oldest bone-headed dinosaur in North America, and possibly the world. Research describing the new species is published May 7, 2013 in the journal Nature Communications.
Acrotholus means "high dome", referring to its ...
ASTRO and AUA issue joint guideline for radiation therapy after prostatectomy
2013-05-07
San Diego, May 7, 2013 – The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence. The 81-page document represents an intensive collaboration among experts in the radiation oncology and urology fields, led by Richard K. Valicenti, MD, MA, professor and chair of the department of radiation oncology at the University of California Davis Comprehensive Cancer Center ...
Discovery of new hormone opens doors to new type 2 diabetes treatments
2013-05-07
Boston, MA — Harvard School of Public Health (HSPH) researchers have discovered that a particular type of protein (hormone) found in fat cells helps regulate how glucose (blood sugar) is controlled and metabolized (used for energy) in the liver. Using experimental models and state-of-the-art technology, the scientists found that switching off this protein leads to better control of glucose production from the liver, revealing a potential new target that may be used to treat type 2 diabetes and other metabolic diseases.
The study appears online in the May 7, 2013 issue ...
The more feathers a male sparrow carries to the nest, the more eggs the female will lay
2013-05-07
An international team lead by the University of Granada has found that female sparrows will invest more energy into laying eggs according to the male's ability to fill the nest with feathers which serve to insulate the chicks from the cold and keep them alive.
Scientists from the University of Granada, in collaboration with the South African University of the Witwatersrand and the Percy FitzPatrick Institute at the University of Cape Town, have discovered that the female house sparrow (Passer domesticus) invests more energy into laying eggs when the male brings more feathers ...